Active-control study to evaluate the safety, tolerance and immunogenicity of Fluviral S/F influenza vaccine in healthy adults aged 18-64 years of age
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2017
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 07 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 07 Jul 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 03 Jul 2007 New trial record.